Genomictree Inc
Korea ExchangeTotal Valuation
Genomictree Inc carries a market capitalization of 517.51B, placing it among publicly traded companies globally. Its enterprise value stands at -75.02B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 517.51B |
| Enterprise Value | -75.02B |
Share Statistics
Genomictree Inc currently has 24.03M shares outstanding.
| Shares Outstanding | 24.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Enterprise Valuation
| EV / Sales | 0.19 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Genomictree Inc maintains a current ratio of 56.88, meaning it holds 56.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.04, indicating conservative leverage, while an interest coverage ratio of -31.99 demonstrates limited ability to service its debt obligations.
| Current Ratio | 56.88 |
| Quick Ratio | 55.58 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -31.99 |
Financial Efficiency
| Return on Equity (ROE) | -30.63 |
| Return on Assets (ROA) | -6.32 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 9.41 |
Stock Price Statistics
Genomictree Inc's stock has declined approximately -6.63717% over the past 52 weeks. The 50-day moving average sits at 19,516.40, while the 200-day moving average is 19,162.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.63717% |
| 50-Day Moving Average | 19,516.40 |
| 200-Day Moving Average | 19,162.55 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Genomictree Inc generated 3.83B in revenue and converted that into -8.02B in net income, yielding earnings per share of -338.68. EBITDA reached -10.60B, while operating income came in at -10.60B.
| Revenue | 3.83B |
| Gross Profit | 853.34M |
| Operating Income | -10.60B |
| Pretax Income | -8.16B |
| Net Income | -8.02B |
| EBITDA | -10.60B |
| EBIT | -10.60B |
| Earnings Per Share (EPS) | -338.68 |
Balance Sheet
Genomictree Inc holds 75.39B in cash and equivalents against 55.19M in total debt, resulting in a net debt position of -8.72B. Total book value stands at 22.52B, with working capital of 75.79B providing operational flexibility.
| Cash & Cash Equivalents | 75.39B |
| Total Debt | 55.19M |
| Net Debt | -8.72B |
| Equity (Book Value) | 22.52B |
| Book Value Per Share | 933.49 |
| Working Capital | 75.79B |
Cash Flow
Genomictree Inc produced -10.64B in operating cash flow over the past twelve months. After subtracting -266.38M in capital expenditures, free cash flow totaled -10.90B - equivalent to -452.00 per share.
| Operating Cash Flow | -10.64B |
| Capital Expenditures | -266.38M |
| Free Cash Flow | -10.90B |
| FCF Per Share | -452.00 |
Margins
Genomictree Inc operates with a gross margin of 22.31, reflecting its pricing power and cost economics. The operating margin of -277.10 and net profit margin of -209.77 provide insight into operational efficiency.
| Gross Margin | 22.31 |
| Operating Margin | -277.10 |
| Pretax Margin | -213.27 |
| Profit Margin | -209.77 |
| EBITDA Margin | -277.10 |
Stock Splits
Genomictree Inc's most recent stock split took place on September 14, 2018 with a 1:2 split ratio.
| Last Split Date | 9/14/2018 |
| Split Ratio | 1:2 |
Scores
Genomictree Inc posts an Altman Z-Score of 0.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.59 |